| Topic | Key facts (with numbers) | Recent/authoritative source (short cite) | Evidence (1-2 sentences) | URL/DOI | Pub year/date |
|---|---|---|---|---|---|
| Disease names / synonyms / IDs | RP2-associated retinitis pigmentosa; Retinitis Pigmentosa 2; X-linked retinitis pigmentosa (XLRP). MeSH: Retinitis Pigmentosa 2 (C567523); Retinitis Pigmentosa (D012174); broader MeSH ancestors include Retinal Dystrophies (D058499), Retinal Degeneration (D012162), Eye Diseases, Hereditary (D015785). OMIM/Orphanet/MONDO not available in provided evidence. | InsightRP2 Registry trial (pqac-00000019) | The ClinicalTrials.gov registry explicitly uses these disease labels and MeSH identifiers, making them suitable controlled-vocabulary terms for a knowledge base. Do not infer OMIM/MONDO IDs from outside sources here. | https://clinicaltrials.gov/study/NCT06982417 | 2025-05-21 |
| Inheritance / gene contribution | X-linked inheritance. RP2 accounts for ~5-20% of XLRP; RPGR accounts for ~60-80% of XLRP. XLRP overall represents ~10-20% of all RP cases. | Pechnikova 2025 J Clin Med; Birch 2023 TVST (pqac-00000026, pqac-00000033) | RP2 is the second major XLRP gene after RPGR. These percentages are useful for prioritizing RP2 within X-linked IRD testing strategies and for contextualizing disease rarity. | https://doi.org/10.3390/jcm14030898; https://doi.org/10.1167/tvst.12.6.5 | 2025-01; 2023-06 |
| Core clinical phenotype / timing | Night blindness, reduced visual acuity, peripheral vision loss; childhood onset with progression to severe impairment by early adulthood. In pediatric data, X-linked RP night blindness median age was 16 years; RP2 juveniles showed severe night blindness and 81% were myopic; younger RP2 patients may present first with high myopia and/or nystagmus; some pediatric rod-cone dystrophy cases were asymptomatic at genetic diagnosis. | Pechnikova 2025 J Clin Med; Priglinger 2024 Int J Mol Sci (pqac-00000021, pqac-00000022, pqac-00000023) | The phenotype is severe and early, but not always symptom-led at first presentation in children. High myopia/nystagmus before nyctalopia is a practical clue that broadens case finding beyond classic symptomatic RP presentations. | https://doi.org/10.3390/jcm14030898; https://doi.org/10.3390/ijms252212259 | 2025-01; 2024-11 |
| Diagnostic workup / RP2-specific differential advice | Standard workup: visual acuity, visual fields/perimetry, full-field ERG, OCT/SD-OCT, OCTA, fundus imaging/FAF. Real-world genetics: panel-based NGS; example 322-gene IRD panel with ACMG classification; Blueprint Genetics panel used in 2022-2024 clinic setting. RP2-specific advice: in young patients with high myopia and ERG anomalies, exclude CACNA1F, RPGR, and RP2 even without night blindness. | Savastano 2024 TVST; Areblom 2023 Genes; Lynn 2024 Genes; Priglinger 2024 Int J Mol Sci (pqac-00000027, pqac-00000032, pqac-00000031, pqac-00000030) | Evidence supports multimodal retinal phenotyping plus comprehensive NGS rather than single-test diagnosis. Pediatric cohort data specifically warn that absence of reported nyctalopia does not exclude RP2-related disease. | https://doi.org/10.1167/tvst.13.8.44; https://doi.org/10.3390/genes14071413; https://doi.org/10.3390/genes16010032; https://doi.org/10.3390/ijms252212259 | 2024-08; 2023-07; 2024-12; 2024-11 |
| Mechanism / pathophysiology | RP2 locus Xp11.23. RP2 is an ARL3 GTPase-activating protein (GAP); functions with UNC119 and PDEδ in trafficking lipidated proteins (e.g., transducin, GRK1, PDE6) to photoreceptor outer segment/cilia. RP2 localizes near basal body/centriole; is cofactor C-like and linked to β-tubulin folding/microtubule network. | Pechnikova 2025 J Clin Med; Frederick 2020 Biol Chem (pqac-00000026, pqac-00000004, pqac-00000005, pqac-00000006) | The disease mechanism centers on defective ciliary/outer-segment trafficking and disturbed photoreceptor protein homeostasis. Frederick et al. add mechanistic detail: RP2 helps establish spatial ARL3-GTP regulation required for destination-specific unloading of lipidated cargo. | https://doi.org/10.3390/jcm14030898; https://doi.org/10.1515/hsz-2019-0375 | 2025-01; 2020-12 |
| Epidemiology / prognosis | RP prevalence ~1:3700-1:8300 worldwide; another estimate 1:3000-1:4000, affecting ~2.5 million globally. X-linked RP is 5-15% to 10-20% of RP depending on source. X-linked disease has the worst prognosis; average visual-field loss 4-12%/year. By age 40, ~20% of XLRP individuals are blind; legal blindness median age ~45 years; complete blindness often by 40-50 years. | Birch 2023 TVST; Savastano 2024 TVST; Pechnikova 2025 J Clin Med (pqac-00000033, pqac-00000034, pqac-00000035) | The numeric burden comes mostly from XLRP and broader RP studies, not RP2-only cohorts, but it consistently supports a severe, rapidly progressive prognosis relative to other RP inheritance classes. These figures are useful for counseling and trial planning. | https://doi.org/10.1167/tvst.12.6.5; https://doi.org/10.1167/tvst.13.8.44; https://doi.org/10.3390/jcm14030898 | 2023-06; 2024-08; 2025-01 |
| Treatments / supportive care | No approved treatment for XLRP in provided evidence. Supportive/symptomatic care includes visual aids, vitamin supplementation, treatment of cystoid macular edema/cataract (anti-VEGF, corticosteroids, cataract surgery), and limited prosthetic approaches such as Argus II. | Birch 2023 TVST; Pechnikova 2025 J Clin Med (pqac-00000039, pqac-00000038, pqac-00000041) | Current care mainly preserves function and quality of life but does not alter progression. This gap underlies the strong push toward gene therapy and natural-history infrastructure. | https://doi.org/10.1167/tvst.12.6.5; https://doi.org/10.3390/jcm14030898 | 2023-06; 2025-01 |
| Experimental / advanced therapies | Preclinical RP2 gene augmentation: self-complementary AAV8-RP2 in mouse models preserved cone function for up to 18 months, improved cone viability, corrected opsin mislocalization, and restored enzyme expression; high-dose retinal toxicity reported. RP2-KO/patient-derived retinal organoids showed rod degeneration by day 150 and ONL thinning by day 180; AAV-RP2 rescue restored rhodopsin expression and degeneration phenotype. | Pechnikova 2025 J Clin Med (pqac-00000042) | These data make RP2 one of the clearer examples where both animal and human organoid rescue support biological plausibility for gene replacement. Toxicity signals emphasize the importance of vector dose optimization. | https://doi.org/10.3390/jcm14030898 | 2025-01 |
| Trials / registries | InsightRP2 Registry: NCT06982417; recruiting observational cohort; estimated n=200; actual start 2025-05-01; primary outcomes include genotype-phenotype correlation for age of onset (1 year) and progression (20 years). Vitamin A trial in RP: NCT00065455; non-randomized pilot, n=10, 50,000 IU/day vitamin A palmitate for 4 weeks then 15,000 IU/day for 2 weeks; ERG-based outcomes; Jul 2003-May 2009. | InsightRP2 Registry; NEI Vitamin A trial (pqac-00000018, pqac-00000017) | InsightRP2 is a practical real-world implementation for natural history, imaging, mutation distribution, and trial readiness in RP2 disease. The vitamin A trial is not RP2-specific, but it shows the historical symptomatic-intervention landscape in RP measured by electrophysiology. | https://clinicaltrials.gov/study/NCT06982417; https://clinicaltrials.gov/study/NCT00065455 | 2025-05-21; 2003-07 to 2009-05 |
| Model organisms | Zebrafish rp2 knockout/knockdown models: early photoreceptor functional defects followed by progressive rod outer-segment degeneration and then cone outer-segment degeneration; decreased/mislocalized GRK1 and rod transducin subunits (GNAT1, GNB1); disrupted distribution of farnesylated proteins. | Noel 2021 Biomolecules; Iribarne 2020 IntechOpen; Pechnikova 2025 J Clin Med (pqac-00000010, pqac-00000009, pqac-00000008, pqac-00000000) | The zebrafish model recapitulates the trafficking-centered mechanism and progressive photoreceptor loss, supporting translational hypothesis generation. However, available reviews note that current animal models may not fully mirror the severe human phenotype. | https://doi.org/10.3390/biom11010078; https://doi.org/10.5772/intechopen.88758; https://doi.org/10.3390/jcm14030898 | 2021-01; 2020-09; 2025-01 |


*Table: This table condenses the most decision-relevant facts on RP2-related retinopathy from the retrieved evidence, including identifiers, phenotype, mechanism, diagnostics, prognosis, and the current translational landscape. It is designed for direct use in a disease knowledge base without adding unsupported identifiers or claims.*